In stomach cancer, USP22 abundance increased from normal tissue to primary carcinoma to lymph node metastasis and was also associated with shorter patient survival (26 vs. 59 months disease-specific survival for USP22-positive vs. -negative primary carcinoma) [12]. This evidence concerns the gene USP22 and gastric cancer.